Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association
Hypertension is a major risk factor for cardiovascular and renal diseases in the United States
and worldwide. Obesity accounts for much of the risk for primary hypertension through …
and worldwide. Obesity accounts for much of the risk for primary hypertension through …
Progress and challenges in anti-obesity pharmacotherapy
DH Bessesen, LF Van Gaal - The lancet Diabetes & endocrinology, 2018 - thelancet.com
Obesity is a serious and growing worldwide health challenge. Healthy lifestyle choices are
the foundation of obesity treatment. However, weight loss can lead to physiological …
the foundation of obesity treatment. However, weight loss can lead to physiological …
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
Importance Individually, cardiac, renal, and metabolic (CRM) conditions are common and
leading causes of death, disability, and health care–associated costs. However, the …
leading causes of death, disability, and health care–associated costs. However, the …
Introduction: the state of obesity in 2017
RF Kushner, S Kahan - Medical Clinics, 2018 - medical.theclinics.com
Assessing where we stand in 2017 is an interesting exercise, now that we are several
decades into the US obesity epidemic. On the one hand, there are several areas of …
decades into the US obesity epidemic. On the one hand, there are several areas of …
Provider practice habits and barriers to care in obesity management in a large multicenter health system
R Simon, SW Lahiri - Endocrine Practice, 2018 - Elsevier
Objective: To identify provider recommendations and barriers in obesity management in a
multicenter academic health system with extensive weight-loss management resources …
multicenter academic health system with extensive weight-loss management resources …
Pharmacotherapy for obesity—trends using a population level national database
A Elangovan, R Shah, ZL Smith - Obesity Surgery, 2021 - Springer
Background Despite the growing trend of obesity, the utilization of anti-obesity therapeutic
interventions is not robust in the USA. We aimed to analyze the trends of anti-obesity …
interventions is not robust in the USA. We aimed to analyze the trends of anti-obesity …
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
DCW Lau, RL Batterham… - Expert Review of Clinical …, 2022 - Taylor & Francis
Introduction The recent approval in the USA (Food and Drug Administration), Canada
(Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU …
(Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU …
Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity
U Holmbäck, A Forslund, S Grudén… - Obesity science & …, 2020 - Wiley Online Library
Objective There is an unmet medical need for a safe and effective weight loss product with
minimal systemic side‐effects. In this study, the effect of a novel modified‐release fixed‐dose …
minimal systemic side‐effects. In this study, the effect of a novel modified‐release fixed‐dose …
[HTML][HTML] Antiobesity medication use among overweight and obese adults in the United States: 2015–2018
Objective To estimate the utilization of US Food and Drug Administration–approved
prescription antiobesity medications (AOMs) and to identify factors associated with AOM use …
prescription antiobesity medications (AOMs) and to identify factors associated with AOM use …
Current practices of obesity pharmacotherapy, bariatric surgery referral and coding for counselling by healthcare professionals
Introduction Rates of obesity pharmacotherapy use, bariatric surgery and intensive
behavioural counselling have been extremely low. Objectives The primary objective of this …
behavioural counselling have been extremely low. Objectives The primary objective of this …